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SUMMARY
The increasing use of primary tumors as surrogate markers for prognosis and therapeutic decisions neglects
evolutionary aspects of cancer progression. To address this problem, we studied the precursor cells of
metastases directly for the identification of prognostic and therapeutic markers and prospectively analyzed
single disseminated cancer cells from lymph nodes and bone marrow of 107 consecutive esophageal cancer
patients. Whole-genome screening revealed that primary tumors and lymphatically and hematogenously
disseminated cancer cells diverged for most genetic aberrations. However, we identified chromosome 17q12–
21, the region comprising HER2, as the most frequent gain in disseminated tumor cells that were isolated
from both ectopic sites. Survival analysis demonstrated that HER2 gain in a single disseminated tumor cell
but not in primary tumors conferred high risk for early death.INTRODUCTION
Despite complete surgical resection of primary cancers, a signif-
icant number of cancer patients die from metastatic spread,
which manifests often years after successful initial surgery.
Lacking a direct access to latent systemic cancer, routine surgi-
cal pathology and modern molecular diagnostic approaches rely
on the analysis of the primary tumor to assess the risk for and the
characteristics of systemic disease. Until today this approach
has been justified by a concept of late metastatic spread. It holdsthat progression of tumor cells to so-called full malignancy
mostly takes place within the primary tumor. However, recent
data demonstrate that dissemination of tumor cells may occur
very early after transformation with metachronous outgrowth af-
ter periods of latency (Hu¨semann et al., 2008). These findings,
combined with the prevailing evolutionary concept of cancer
progression (Cairns, 1975), clearly discourage simple extrapola-
tions from local to systemic disease. Rather, the evolutionary
model predicts an allopatric evolution of variant tumor cells for
survival and proliferation in different microenvironments andSIGNIFICANCE
After curative resection of primary tumors, outgrowth of micrometastatic cells is the major cause for death from cancer.
Therefore, therapy targets on the metastatic precursor cells are urgently needed. The finding that HER2 is a prognostic
marker only when amplified in disseminated esophageal cancer cells but not when amplified in primary tumors is an exam-
ple of a clinically important divergence of local disease and early systemic cancer. Since HER2 is an important molecular
drug target, the results question the dominant role of primary tumors as surrogate markers for patient stratification and
for therapy target research. The development of a pathology for minimal systemic cancer may therefore overcome the
limitations inevitably linked to conventional diagnostic studies of primary tumors.Cancer Cell 13, 441–453, May 2008 ª2008 Elsevier Inc. 441
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DTC Profiling for Prognosis and Therapy Selectionconsequently genetic divergence (Klein, 2003). Direct genetic
comparisons of primary tumors and matched clinically manifest
metastases are surprisingly sparse but revealed a wide range of
possible outcomes, from completely unrelated to genetically
very similar (Kuukasjarvi et al., 1997). In addition, such compar-
ative studies on the two endpoints of local and systemic disease
do not reflect the evolutionary dynamics during the time of la-
tency from dissemination of precursor cells to manifestation of
metastases. Therefore, while the endpoints (i.e., the excised pri-
mary tumor and the overt metastases) might concur on some ge-
netic alterations, it is unclear whether shared genetic aberrations
reflect the general tendency of solid cancers to accumulate
similar aberrations independently during outgrowth (Heim and
Mitelman, 1995; Hoglund et al., 2002) or true clonal descent.
Early carcinoma spread before manifestation of distant metas-
tasis is detected by immunostaining for epithelial cells in mesen-
chymal organs such as lymph nodes, bone marrow, or blood
(Klein, 2003; Pantel et al., 2003). Cytokeratin antibodies for de-
tection of disseminated tumor cells in bone marrow and EpCAM
(epithelial cell adhesion molecule) antibodies in lymph nodes
proved to be specific and reliable prognostic markers, with a sin-
gle tumor cell among 2 3 106 bone marrow or lymph node cells
sufficing to predict poor clinical outcome in breast and esopha-
geal cancer (Braun et al., 2005; Izbicki et al., 1997). The genetic
analysis of cells detected by these markers demonstrated that at
least some human cancers spread early (Schardt et al., 2005;
Schmidt-Kittler et al., 2003) and develop from genetically hetero-
geneous tumor cells to clonally expanded and selected cells at
the metastatic stage of disease (Klein et al., 2002a).
Since therapeutic interventions after manifestation of metasta-
sis are notoriously ineffective for most cancers, we tested the hy-
pothesis that a better understanding of the actual, dynamic evo-
lutionary processes taking place systemically before this stage
provides different clinical information than analysis of the primary
tumor. We investigated esophageal cancer in a prospective
study, because it is one of the most aggressive human cancers
with most curatively operated patients relapsing within 5 years
(Enzinger and Mayer, 2003). A recent study comparing chemora-
diotherapy alone with chemoradiotherapy followed by surgery
for patients with esophageal cancer demonstrated that neither
distant metastasis nor overall survival differed between the
groups despite a lower rate of local tumor recurrence in the sur-
gical group (Bedenne et al., 2007). It was concluded that meta-
static disease determines survival and that the hope for the
future is the development of more specific targeted therapies
to eradicate or suppress the growth of micrometastatic disease
(Ilson, 2007). To address this need we analyzed micrometastatic
disease directly and isolated and compared single disseminated
cancer cells from lymph nodes and from bone marrow to cover
the two types of metastatic spread.
RESULTS
Detection and Whole-Genome Analysis
of Single Disseminated Cancer Cells
Of 107 consecutive patients, we screened 104 bone marrow
samples and 35 lymph node preparations from 18 patients
with operable esophageal cancer (Table 1) for disseminated
tumor cells (DTCs). As several molecular techniques were442 Cancer Cell 13, 441–453, May 2008 ª2008 Elsevier Inc.Table 1. Clinicopathologic Data of Analyzed Patients
Prospective
Study (%)
Included in
Survival
Analysisa (%)
Extended
Primary Tumor
Cohort (%)
Patients 107 62 101
Male 88 (82) 50 (81) 79 (78)
Female 19 (18) 12 (19) 22 (22)
Histology
ADC 51 (52) 32 (53) 71 (70)
SCC 56 (48) 30 (47) 30 (30)
Primary Tumor
pT1 16 (15) 13 (21) 19 (19)
pT2 33 (31) 23 (37) 38 (37)
pT3 46 (43) 24 (39) 40 (40)
pT4 12 (11) 2 (3) 4 (4)
Lymph Node Status
pN0 31 (29) 23 (37) 31 (31)
pN1 76 (71) 39 (63) 70 (69)
Tumor Grade
G1 3 (3) 2 (3) 1 (1)
G2 55 (51) 31 (50) 51 (50)
G3 49 (46) 29 (47) 49 (49)
Resection Margins
R0 87 (81) 52 (84) 97 (96)
R1 12 (11) 10 (16) 4 (4)
R2 8 (8) 0 (—) 0 (—)
AJCC Stage
I 13 (12) 11 (18) 15 (15)
IIa 17(16) 12 (19) 16 (16)
IIb 22 (21) 17 (27) 31 (30)
III 31 (29) 14 (23) 33 (33)
IV 24 (22) 8 (13) 6 (6)
HER2 Primary Tumor
Amplification 13 (12) 7 (17) 18 (18)
No Amplification 61 (57) 42 (83) 83 (82)
Missing 33 (31) 14 (—) 0 (—)
Synchronous Distant Organ Metastasis (M1b)
No 94 (88) 62 101
Yes 13 (12) 0 0
DTC (Bone Marrow or Lymph Node)
No 63 (59) 38 (61) —
Yes 44 (41) 24 (39) —
17q12–21 in DTC (Bone Marrow or Lymph Node)
No 90 (84) 50 (81) —
Yes 17 (16) 12 (19) —
HER2 DTC (Bone Marrow or Lymph Node)
No 98 (92) 56 (90) —
Yes 9 (8) 6 (10) —
a Includes only patients whose cells were genetically analyzed and for
whom survivalR 3 months and R < 2.
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DTC Profiling for Prognosis and Therapy Selectionperformed on several samples of one individual patient (e.g.,
primary tumor, DTCs from bone marrow, and/or lymph node),
which may cause confusion, Figure 1 depicts the study outline
and includes numbers of patients and samples. Tumor cells
that disseminated to bone marrow were detected in 38/104
(37%) cases by the mAB A45-B/B3 directed against cytokeratins
8, 18, and 19 (Figure 2A) and in 9/18 (50%) lymph node samples
by an antibody against the epithelial cell adhesion molecule
(EpCAM; mAb Ber-Ep4). In bone marrow and lymph node sam-
ples, 17% and 39% of patients, respectively, harbored more
than one marker-positive cell (Figure S1 available online). From
all positive samples, we successfully isolated 60 of the positive
cells (Figure 2A, 44 cells from bone marrow and 16 cells from
lymph nodes) from 35 patients and prepared their DNA for global
amplification by PCR. Then, we performed single-cell compara-
tive genomic hybridization (SCOMP) on metaphase spreads
(Klein et al., 1999; Schmidt-Kittler et al., 2003), which currently al-
lows the most reliable overview of chromosomal DNA gains and
losses present in single disseminated esophageal cancer cells
(Figure 2B). Among several chromosomal DNA gains and losses
typical for this cancer (Figure 2C), we observed the highest num-
ber of gains for 17q12–21 (22 of 60 cells; 37%), the region of the
HER2 gene locus. This chromosomal region was significantly
more often gained in cells derived from esophageal adenocarci-
nomas (ADC; 19/33, 58%) than in cells derived from esophageal
squamous cell carcinomas (SCC; 3/27, 11%; p < 0.001, Fisher’s
exact test; Figure 2C). We then compared the genetic aberra-
tions in cells isolated from bone marrow and lymph nodes
(Figure 2D). First, in 12 cases (n = 32 cells) we had isolated
Figure 1. Experimental Outline of the Prospective Study
Disseminated tumor cells (DTCs) were detected by cytokeratin staining in
bone marrow and by EpCAM staining in lymph nodes. For each experi-
mental analysis, numbers of cells and patients are indicated.
more than one tumor cell displaying CGH aberrations from
one of the organs and detected in three cases aberrant tumor
cells in both organs of an individual patient. Here, the tumor
cells from one organ (either bone marrow or lymph node) dis-
played mostly similar aberrations (Figure 2E), however, in all
three cases with concomitantly isolated tumor cells from
bone marrow and lymph nodes, the tumor cells from different
organs shared almost no genomic aberrations (Figure 2E).
This genetic divergence between the tumor cells isolated
from the different microenvironments was also observed
for all tumor cells (Figure 2D). For example, gains of chromo-
somes 7q and 10q and a loss at 5q were frequently found in
DTCs isolated from lymph nodes while almost never ob-
served in tumor cells from bone marrow. In contrast, the fre-
quency of 17q12–21 gains did not differ significantly be-
tween tumor cells isolated from bone marrow or from
lymph nodes (for ADC: lymph node 7/10 cells versus bone
marrow 12/23 cells; for SCC: lymph node 2/6 versus bone
marrow 1/21; Fisher’s exact test, p = 0.46 and p = 0.12, re-
spectively). This indicated that, while several aberrations di-
verged between cells disseminating to bone marrow and to
lymph nodes, the region of 17q12–21 was equally gained in
tumor cells disseminating via one of the two routes of systemic
spread.
Assessment of HER2 Gains in Single Disseminated
Cancer Cells
Therefore, 17q12–21 aberrations might be relevant for systemic
cancer spread. Because resolution of metaphase CGH ranges
from 10 to 20 Mb, direct identification of amplified genes is im-
possible. As a potential candidate we selected the HER2 gene
for a gene-specific quantitative (q) PCR assay (Figures 3A and
3B). This assay was established and validated using whole-ge-
nomic amplification products of single metastatic breast cancer
cells (Schardt et al., 2005) and can be applied to the very same
genomic DNA from a single cell that had been used for CGH
analysis. qPCR for the HER2 gene was successfully performed
with 58 of the 60 isolated single disseminated tumor cells. Inter-
estingly, using the qPCR assay two disseminated tumor cells
were found to have a HER2 gene gain, which had escaped de-
tection by metaphase CGH. On the other hand, only 11/22
(50%) cells, in which CGH had uncovered chromosomal gains
in the proximity of 17q12–21, had a HER2 gene gain.
Genetic Aberrations in Disseminated Cancer Cells
and Patient Survival
We then evaluated whether HER2 or 17q12–21 gains in dissem-
inated esophageal cancer cells put the patients at risk for death.
Sixty-two patients were eligible for survival analysis following the
intention-to-treat principle (Table 1 and Experimental Proce-
dures) and were distributed into four groups: patients withoutCancer Cell 13, 441–453, May 2008 ª2008 Elsevier Inc. 443
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DTC Profiling for Prognosis and Therapy SelectionFigure 2. Whole-Genome Screen of Single Disseminated Esophageal Tumor Cells
(A) Isolation of a single cytokeratin-positive cell by micromanipulation (white arrow, tumor cell; black arrows, unstained bone marrow cells). The cell is transferred
to a new slide to visually control that no other cells are coisolated (right, lower panel).
(B) Metaphase spread hybridized with the amplified genome of a single tumor cell. Arrows indicate bright hybridization signal on chromosome 17, subsequently
identified as HER2 gene gain. Scale bar, 5 mm.
(C) Horizontal histograms depicting the chromosomal gains (green) and losses (red) of disseminated tumor cells isolated from SCC and ADC esophageal cancer
patients, respectively. Arrows indicate the chromosomal region 17q12–21.
(D) Horizontal histograms depicting the genomic profiles of tumor cells isolated from bone marrow (BM) and lymph nodes (LN), respectively. Note that changes at
chromosome 5, 7, and 10 (arrows) frequently observed in tumor cells from lymph nodes are rare in tumor cells isolated from bone marrow. The asterisk indicates
the region 17q12–21.
(E) Hierarchical cluster analysis of disseminated tumor cells isolated from bone marrow and lymph nodes. Thirty-two tumor cells from 12 patients were clustered
to assess their genetic similarity. Only patients in whom we had isolated more than one tumor cell were selected. Several tumor cells were either detected in one
organ (bone marrow or lymph node) or in both compartments of one individual patient. Identifiers consist of patient number, BT for bone marrow-derived tumor
cell, LT for lymph node-derived tumor cell, and cell identifier. Cases 2357, 2548, and 3439 harbored DTC in both bone marrow and lymph node. Note that, even in
case 2357, for which BM and LN cells are grouped in relative proximity, almost no aberrations are shared. Cells from one individual patient that cluster together
are marked with a bar.disseminated cancer cells in bone marrow or lymph nodes
(n = 38); patients with disseminated cancer cells that harbored
no aberration on chromosome 17q12–21 (n = 12); patients with
a gain of chromosome 17q12–21 but without HER2 gain
(n = 6); and finally, patients whose cells displayed a HER2 gain
in our qPCR assay (n = 6). Among the four groups, patients
withHER2-amplified cancer cells had an extremely poor survival444 Cancer Cell 13, 441–453, May 2008 ª2008 Elsevier Inc.(Figure 3D, log rank test, p = 0.032, df = 3) with no patient surviv-
ing longer than 23 months. Although previous studies demon-
strated a significant prognostic impact of DTCs in esophageal
cancer (Hosch et al., 2001; Izbicki et al., 1997; Thorban et al.,
2000), the presence of DTCs alone did not confer a significant
risk in our group of patients (log rank test, p = 0.134). However,
when six additional patients with DTCs were added, for which
Cancer Cell
DTC Profiling for Prognosis and Therapy SelectionFigure 3. Identification and Prognostic Impact of HER2 Gains in Disseminated Tumor Cells and Primary Tumors
(A and B) Quantitative PCR assay for the HER2 gene and for a reference gene of two cytokeratin-positive cells with (solid line) and without (thin line) HER2
amplification. The HER2 gain is indicated by the significantly lower Ct value (20 versus 26) at the HER locus (B), while an almost equal Ct value (25.5 versus 26.5)
was observed at the reference gene (A).
(C) FISH analysis of an ADC primary tumor with HER2 amplification (E, red: HER2 and green: chromosome 17 centromer). Scale bar, 10 mm.
(D) Impact of disseminated tumor cell status on overall survival (all, n = 62; DTC, disseminated tumor cells [n = 12]; 17q12–21, DTC harboring chromosomal gain of
17q12–21 but no HER2 gain [n = 6]; HER2 gain, patients with DTC that display HER2 gain [n = 6]).
(E) Impact of HER2 amplifications in matched primary tumors (all, n = 49; HER2 A, HER2 amplification detected by FISH [n = 7]).
(F) Overall survival of patients with disseminated tumor cells that display HER2 gain by qPCR compared to all other patients (all, n = 62; HER2 gain, patients with
DTC that display HER2 gain [n = 6]).
(G) Overall survival of patients with and withoutHER2 amplification analyzed by FISH in primary tumors (all, n = 101; HER2 A,HER2 amplification detected by FISH
[n = 18]).no genetic data were available, a tendency for increased risk was
observed (log rank test, p = 0.09). In the clinically relevant com-
parison of patients with HER2-amplified disseminated cancer
cells against all other patients, we found a strong impact
on survival upon univariate analysis (Figure 3F; log rank test,p = 0.005). Upon multivariate analysis,HER2 amplification in dis-
seminated cancer cells proved to be a very important risk factor.
Of the other factors tested (age, lymph node status, tumor size,
tumor grade, histology, and resection margin) only tumor size
was also an independent risk factor and was included into theCancer Cell 13, 441–453, May 2008 ª2008 Elsevier Inc. 445
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DTC Profiling for Prognosis and Therapy SelectionTable 2. Multivariate Survival Analysis of Prognostic Factors in the Disseminated Tumor Cell Collective
Univariate Analysis Multivariate Analysis
Risk Factora Median Survival in Months p Value Relative Risk (95% CI) p Value
Age: <60 years (n = 29) versusR60 years (n = 33) 28.0 versus 19.7 0.510 neb —
Histology: SCC (n = 30) versus ADC (n = 32) 18.0 versus 26.1 0.058 ne —
Lymph node status: pN1 (n = 39) versus pN0 (n = 23) 22.9 versus 36.3 0.077 ne —
Primary tumor size: pT3–4 (n = 26) versus pT1–2 (n = 36) 19.7 versus 31.6 0.007 2.31 (1.26–4.23) 0.006
Tumor grading: G3–4 (n = 33) versus G1–2 (n = 29) 12.9 versus 26.10 0.709 ne —
Resection margin: R0 (n = 51) versus R1 (n = 11) 26.1 versus 17.2 0.129 ne —
Disseminated tumor cells in bone marrow or lymph nodes:
present (n = 24) versus absent (n = 38)
18.8 versus 28.2 0.134 — —
Cytokeratin-positive cells in bone marrow: present (n = 22)
versus absent (n = 40)
18.2 versus 28.2 0.138 — —
HER2 amplification in a single disseminated tumor cell:
present (n = 6) versus absent (n = 56)
11.5 versus 26.1 0.005 3.57 (1.45–8.80) 0.006
Patients: n = 62.
a Sample numbers are given in parenthesis.
b ne, not entered into the final multivariate analysis model.final model (Table 2). When we only included R0 patients (n = 52)
in the multivariate analysis, HER2 gain in DTCs was the only fac-
tor included into the model (p = 0.018; relative risk: 3.321;
CI = 1.226–8.997). Likewise, rescue treatment of 11 patients by
chemoradiotherapy had no effect on survival (log rank test
p = 0.61). HER2 status in disseminated cancer cells was not
significantly different for patients with and without rescue treat-
ment (Fisher’s exact test, p = 0.58).446 Cancer Cell 13, 441–453, May 2008 ª2008 Elsevier Inc.HER2 Amplifications in Primary Tumors and Survival
We compared these results with the prognostic impact of HER2
amplifications when present in primary tumors as determined by
a standardized fluorescence in situ hybridization (FISH) assay
(Figure 3C). Of the same patient group, for which we had ana-
lyzed the effect of DTCs, we could successfully test 49 patients
for HER2 amplification in the primary tumor. No effect of the am-
plification on survival was observed (Figure 3E, p = 0.229). ToFigure 4. Whole-Genome Comparison of Single Disseminated Cancer Cells and Matched Primary Tumors
(A) Hierarchical cluster analysis of the CGH aberrations of 33 single cells isolated from five different breast cancer cell lines. Note that all single cells from each cell
line are grouped according to their origin—regardless of the degree of chromosomal instability.
(B) Hierarchical cluster analysis of disseminated tumor cells that harbor HER2 gains and their matched primary tumors. (Identifiers consist of patient number, BT
for bone marrow-derived tumor cell, LT for lymph node-derived tumor cell, PT for primary tumor, and cell identifier.)
Cancer Cell
DTC Profiling for Prognosis and Therapy SelectionFigure 5. Evaluation of HER2 as a Potential Target for
Adjuvant Treatment of Esophageal Cancer Patients
(A–C) Double staining of DTCs in lymph node samples. Scale
bars, 20 mm. (A) EpCAM-positive cells in lymph node. (B) The
same cells and one additional cell stained by an antibody di-
rected against HER2. (C) Bright-field demonstrating that the
surrounding lymph node cells are negative for EpCAM and
HER2 (arrowheads). White arrow points at EpCAM/HER2 dou-
ble-positive cell; black arrow points at HER2 single-positive
cell.
(D and E) CGH profile of chromosome 17 indicating copy num-
ber gain at 17q12–21 for EpCAM/HER2 double-positive cell
and for the HER2 single-positive cell.
(F and G) Dual-color FISH analysis with probes against the
HER2 locus (red) and chromosome 17 centromer (green) of
PT1590 (F) and LN1590 (G) showing HER2 amplification in
both cell lines. Scale bars, 5 mm.
(H) Immunofluorescence using a FITC-conjugated trastuzu-
mab revealing p185 overexpression of LN1590. Scale bar,
20 mm.
(I) Growth inhibition (mean values ± SEM, n = 3) after 72 hr of
trastuzumab (10 mg/ml) treatment relative to untreated cells.
(J) Standard ADCC assay exposing target cells to trastuzumab
for 4 hr. Error bars indicate ± SD from mean in triplicate deter-
minations.
(K) Frequency of disseminated tumor cells with HER2 gain in
the bone marrow of breast and esophageal cancer patients
(SCC, esophageal squamous cell carcinoma, patients, n = 14;
cells, n = 27; ADC, esophageal adenocarcinoma, patients, n =
18; cells, n = 27; breast, breast cancer; patients, n = 56; cells,
n = 87). Patients were assigned as positive, when at least one
tumor cell displayed a HER2 gain.confirm this result, we added 52 unselected patients for which
we could analyze the primary tumor for HER2 gene amplification
but had no data on the presence of DTCs. Also in this extended
primary tumor cohort (Table 1, n = 101),HER2 gene amplification
had no effect on the survival of the patients (Figure 3G, p =
0.704). Thus, direct analysis of single DTCs had identified a
genetic risk factor only relevant when present in DTCs. In 30 of
the 35 cases from which we isolated marker-positive tumor cells,
we were able to compare the HER2 status of the DTCs and their
matched primary tumors. The presence of HER2 amplifications
in primary tumors and DTCs was not congruent. For example,
if selection for HER2-based therapy would rely on the analyses
of primary tumors as it is currently done for breast cancer pa-
tients, four out of ten eligible cases would be missed (Table S1).
Genomic Divergence between Local
and Systemic Cancer
To test whether the genetic divergence between the primary tu-
mors and the DTCs applies only to theHER2 gene, we compared
their global patterns of genomic aberrations. We first assessed
the reliability of our single-cell CGH when evaluated by hierarchi-
cal cluster analysis. We isolated 33 single cells from five different
genomically well-characterized breast cancer cell lines and per-
formed single-cell CGH analysis. All cells were correctly grouped
according to their origin, although the individual cells displayed
different degrees of genetic variation. Moreover, the finding
that none of the single cells from the cell line CAL51—known
to have a completely normal karyotype—displayed any chromo-
somal changes, strongly supports the validity of the analysis
(Figure 4A). In striking contrast, primary tumors and matchedDTCs from esophageal cancer patients were grouped remotely
from each other in one of the two major branches of the dendro-
gram, indicating rather different and often opposing patterns of
genomic changes (Figure 4B). The results demonstrate that pri-
mary tumors are inadequate surrogate markers for the genetics
of early systemic esophageal cancer and suggest that direct
analysis of single DTCs will uncover currently unknown genetic
changes relevant for systemic progression.
HER2 as a Potential Target for Adjuvant Therapy
in Esophageal Cancer
The applied whole-genome screen of DTCs and the survival
analysis identified a potential therapy target, the HER2 gene
product, for treatment of micrometastases in a subgroup of
esophageal cancer patients. We therefore gathered additional
data that support an adjuvant therapy of esophageal cancer pa-
tients directed against HER2. First, from seven patients addi-
tional slides from disaggregated lymph nodes were available
for double staining of EpCAM (the marker to detect DTCs in
lymph nodes) and p185, the gene product of HER2. In two
samples we detected three disseminated tumor cells that all
expressed p185/HER2. Interestingly, one of two cells from one
patient strongly expressed p185/HER2, while EpCAM could
not be detected (Figures 5A–5C). Moreover, in both cells we
found gains at the HER2 region—subsequently confirmed by
qPCR—among multiple chromosomal aberrations, thereby
proving the malignant origin (Figure 5D). These findings suggest
that p185/HER2 is expressed in DTCs with HER2 gain, and that
the antigen could be targeted by trastuzumab, an antibody di-
rected against p185/HER2. We therefore tested whetherCancer Cell 13, 441–453, May 2008 ª2008 Elsevier Inc. 447
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DTC Profiling for Prognosis and Therapy SelectionFigure 6. HER2-Directed Inhibition Reveals Oncogene Dependence of LN1590 but Not PT1590 Cells
(A) HER2/p185 protein expression relative to the mammary cell line SKBR3 by densitometric evaluation of western blots.
(B) Representative western blot of the HER2 knockdown. Cells have been lysed 48 hr after siRNA treatment, and 35–50 mg of total lysate have been loaded on
a 7.5% acrylamid-gel (KD = knockdown, C = siRNA control). Tubulin is shown as loading control.
(C) Mean values and standard error (n = 3) of the densitometric analysis for each HER2 knockdown performed. Histogram shows the HER2 knockdown efficiency
as a percentage of the siRNA control.448 Cancer Cell 13, 441–453, May 2008 ª2008 Elsevier Inc.
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in vitro and focused in particular on cells that were generated
from patient 1590. So far this is the only esophageal ADC patient
of whom cell lines could be generated both from the primary tu-
mor (PT1590) and from disseminated tumor cells (LN1590) in
a lymph node that had been judged macroscopically free of tu-
mor (Hosch et al., 2000). Both DTC-derived and primary tu-
mor-derived cell line cells harbor HER2 amplifications and over-
express p185 (Figures 5F–5H). Upon trastuzumab treatment
growth arrest was observed for LN1590 and PT1590 cells alike,
as well as for the ADC cell line OE33, but not for the two esoph-
ageal SCC cell lines, Kyse270 and Kyse410 (Figure 5I). The two
Kyse cell lines display a trisomy of chromosome 17, whereas
OE33 displays true HER2 gene amplification upon FISH analysis
(data not shown). LN1590 cells and PT1590 cells were then
tested in an antibody-dependent cellular cytotoxicity assay
(ADCC-assay). Since ADCC is a known effector mechanism of
trastuzumab activity (Carter, 2001; Curcio et al., 2003; Prang
et al., 2005), this assay allowed determining the preclinical sen-
sitivity to trastuzumab treatment. LN1590 and PT1590 cells were
lysed by effector cells with a concentration that has previously in-
dicated clinical efficacy (Prang et al., 2005) and did not affect the
p185/HER2-negative MCF7 cell line (Figure 5J). This suggests
that esophageal cancer patients displaying a HER2 gain in dis-
seminated cancer cells would likewise benefit from adjuvant
treatment with trastuzumab. Moreover, when we compared the
incidence of DTCs displaying a HER2 gain in bone marrow of
nonmetastatic (stage M0) esophageal cancer patients with M0
stage breast cancer patients, for whom adjuvant therapy with
trastuzumab was recently approved by the FDA, we found
HER2 gains in DTCs to be significantly more frequent in patients
with esophageal adenocarcinomas than in breast cancer (p =
0.04 for patients and p = 0.02 for cells; Figure 5K).
Differential Response of PT1590 and LN 1590 Cells
to HER2 Inhibition
It has been repeatedly observed that targeted therapies are only
effective when the tumor cells are depending on the targeted
mechanisms, a phenomenon that has been termed oncogene
addiction (Weinstein and Joe, 2006) and is most often observed
when the targeted mechanism is activated by genetic alter-
ations. For example, EGFR is often overexpressed in lung and
colon cancers; however, therapy responses are only observed
when EGFR is mutated or amplified (Lynch et al., 2004; Moroni
et al., 2005). The surprising divergence of primary tumors and
DTCs for HER2-associated relapse prompted us to explore
whether the DTC-derived LN1590 cells and the primary tumor-
derived PT1590 cells are equally dependent on the HER2gene—despite the fact that both cell lines harbor HER2 amplifi-
cations. We therefore inhibited HER2 signaling by siRNA-medi-
ated knockdown in both cell lines. Relative to the mammary
cell line SKBR3, used as positive control, PT1590 and LN1590
expressed about 50% of p185/HER2 (Figure 6A), and HER2/
p185 knockdown was similar for PT1590 and LN1590 (Figures
6B and 6C). However, growth inhibition and the induction of ap-
optosis were much stronger in LN1590 cells than in PT1590 cells
(Figures 6D and 6E), indicating that LN1590 cells are more de-
pendent on HER2 activation than PT1590 cells. Of the other
cell lines, OE33 cells also responded strongly to the siRNA
treatment (Figures 6D and 6E).
To extend these observations to additional clinically used in-
hibitors of HER2 signaling, we tested the effects of lapatinib,
and erlotinib. Both inhibitors are known to affect HER2 signaling,
although erlotinib was originally thought to inhibit EGFR only
(Schaefer et al., 2007). SKBR3 and Kyse270 served as positive
and negative controls, respectively, and responded as expected
(Figure 6F). LN1590 cells but not in PT1590 cells responded
strongly to lapatinib (Figure 6F), and LN1590 cells were also ef-
fectively inhibited and killed by erlotinib in contrast to PT1590
cells (Figures 6G and 6H). Thus, the low IC50 concentrations of
both lapatinib and erlotinib further support the stronger depen-
dence of LN1590 cells on HER2 signaling as opposed to
PT1590 cells.
DISCUSSION
Our study evaluates the evolutionary model of cancer progres-
sion for potential clinical consequences and describes profound
differences between local and early systemic disease. Divergent
genetic aberrations were observed not only between primary tu-
mors and DTCs from ectopic sites, but also specifically between
tumor cells isolated from lymph nodes and from bone marrow.
These observations most likely reflect the ongoing selection
and expansion of genetically variant tumor cells and point to cur-
rently unrecognized evolutionary dynamics of disease progres-
sion, which may even exceed what we observed in our limited
analysis. First, a complete description of the genomic trajecto-
ries from local to systemic disease would—in addition to DTC
analysis—require inclusion of manifest lymph node and distant
metastasis. Second, our analysis of genomic divergence was
based on metaphase CGH. Since metaphase CGH has a limited
resolution, it may miss both the true extent of genetic divergence
as well as small genetic alterations (e.g., point mutations, small
subchromosomal alterations) that are shared between all prog-
eny of the initiating primary lesion. In breast cancer, we previ-
ously demonstrated the existence of such shared small(D) Mean values ± SEM (n = 3) of the growth inhibition after the HER2 knockdown relative to the siRNA control (GL2), measured by MTT assay 72 hr after cell
seeding and 96 hr after the HER2 knockdown.
(E) Percentage of apoptosis (mean values ± SEM) measured by FACS analysis (sub-G1 content) after 72 hr (96 hr after the HER2 knockdown). KD, knockdown
with HER2-directed oligo; , control oligo GL2.
(F) Growth inhibition and induction of apoptosis by lapatinib treatment. Cell growth (black line) and apoptosis (red line) of SKBR3 (solid line) and Kyse270 (dashed
line; left panel) and of LN1590 (solid line) and PT1590 (dashed line; right panel) after treatment with indicated concentrations of lapatinib for 72 hr. Mean values ±
SEM.
(G) Growth inhibition and induction of apoptosis by erlotinib treatment. Cell growth (black line) and apoptosis (red line) of SKBR3 (solid line) and Kyse270 (dashed
line; left panel) and of LN1590 (solid line) and PT1590 (dashed line; right panel) after treatment with indicated concentrations of erlotinib for 72 hr. Mean values ±
SEM.
(H) IC50 concentrations for lapatinib and erlotinib.Cancer Cell 13, 441–453, May 2008 ª2008 Elsevier Inc. 449
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divergence of chromosomal aberrations (Schardt et al., 2005).
The search for genetic defects shared by all tumor cells will be
particularly important because genetic activation of an onco-
genic pathway often underlies oncogene dependence—a pre-
requisite for clinical response to targeted therapies (Weinstein
and Joe, 2006). However, we cannot exclude that some of the
genetic differences between DTCs from bone marrow and lymph
nodes are not (only) related to the isolation from different micro-
environments but also characterize epigenetically different tu-
mor cell populations because we had to use different markers
for detection. We applied the most specific markers, EpCAM an-
tibodies for lymph node samples and cytokeratin antibodies for
bone marrow, because cytokeratin-positive cells have been de-
tected in lymph nodes (Passlick et al., 1994) and EpCAM-positive
cells in bone marrow of control patients without malignancy
(Klein et al., 2002b). Regardless of whether some genetic differ-
ences are associated with the specific detection method,
17q12–21 gains were the most frequent genomic aberration in
both types of tumor cells, indicating that this region harbors
genes that support both hematogenous and lymphatic cancer
progression. Since metaphase CGH does not identify affected
genes, we tested the obvious candidate mapping within this re-
gion, the HER2 gene, by gene-specific quantitative PCR. In 50%
of 17q12–21 gains, the HER2 gene was gained both in tumor
cells from lymph nodes and bone marrow. Interestingly, only
gain of HER2 but not of 17q12–21 without HER2 gain was indic-
ative for poor survival, suggesting thatHER2 gains are critical for
systemic esophageal cancer.
Having observed the genetic divergence of cancer cells dis-
seminated by the way of blood or lymph, we were not surprised
that local disease differed from systemic cancer as well. While
a gain of HER2 in a single disseminated cancer cell was an im-
portant risk factor in multivariate analysis, HER2 amplification
in primary tumors was not associated with poor survival either
in the group of patients that were analyzed for disseminated can-
cer cells or in a study cohort comprising twice as many patients.
Our group of patients analyzed for HER2 amplification is one of
the largest of esophageal cancer patients, and the findings are
in agreement with previous studies observing the lack of prog-
nostic impact of HER2 amplification in primary esophageal can-
cers (Reichelt et al., 2007). It should be noted that we applied dif-
ferent methods to determine the HER2 status in single tumor
cells and primary tumors. Standard FISH analysis was used for
primary tumors, whereas quantitative PCR served to determine
HER2 gains in single disseminated cancer cells. All single dis-
seminated cells identified by cytokeratin or EpCAM antibodies
were isolated, and their genomic DNA was globally amplified
and used for CGH and subsequently for qPCR of the HER2
gene. A HER2 gain was assigned to any isolated cell with signif-
icantly higher amounts of HER2 sequence as compared to 50
single normal control cells using a robust rank sum test (Schardt
et al., 2005). It will be interesting to test whether FISH analysis of
single disseminated cancer cells will be equally reliable for the
identification of patients with short survival.
The differential prognostic impact of HER2 gains in DTCs and
primary tumors was paralleled by differential responses of the
LN1590 and PT1590 cell lines to HER2 inhibition. These cell lines
were isolated from DTCs (LN1590) and the primary tumor450 Cancer Cell 13, 441–453, May 2008 ª2008 Elsevier Inc.(PT1590) of a patient with esophageal cancer. While both cell
lines displayed HER2 gene amplification and protein overex-
pression, only LN1590, the DTC-derived cell line, responded to
HER2-directed siRNA and to the HER2/EGFR inhibitors lapatinib
and erlotinib with increased apoptosis and growth inhibition. So
far, it raises the interesting, yet puzzling and worrisome possibil-
ity not only that selection during systemic progression results in
divergent genomes, as shown by the gene copy number analy-
sis, but also that genes that are genetically altered in similar
ways may play different roles in local and systemic disease.
This conclusion has to be drawn with caution first, because the
functional data are based on cell lines, which might have been
selected in culture, and second, because PT1590 and LN1590
are currently the only available pair of cell lines derived from
the primary tumor and from DTCs of the same patient.
Since genetic activation of a therapy target molecule has been
demonstrated to be often essential for treatment response to
various targeted therapies (Arteaga and Baselga, 2004; Wein-
stein and Joe, 2006), the finding of HER2 gains in single dissem-
inated cancer cells may provide a rationale for the stratification of
esophageal cancer patients for adjuvantHER2-based therapies.
Such targeting of HER2 in future trials may primarily focus on
esophageal adenocarcinomas, because HER2 gains in DTCs
were more frequent in patients with ADC than in SCC (39% ver-
sus 6%; Figure 5K). It is noteworthy that more M0-stage ADC pa-
tients with DTCs harbored HER2-positive cells in bone marrow
than M0-stage breast cancer patients with DTCs (39% versus
16%; Figure 5K), while the incidence of HER2 amplifications in
primary tumors is about 15%–17% for both tumor types (Al-Kur-
aya et al., 2004; Reichelt et al., 2007). While it is unknown
whether the more frequent gain of HER2 in DTC of ADC com-
pared to breast cancer patients contributes to the generally
more aggressive course of esophageal cancer, another observa-
tion differentiates esophageal cancer from breast cancer. In M0-
stage breast cancer patients, individual DTCs from bone marrow
displayed heterogeneous chromosomal aberrations, while DTCs
from breast cancer patients with manifest metastases were ge-
netically similar (Klein et al., 2002a). Others and we interpreted
this observation as a process of clonal selection and expansion
taking place during a period of latency to manifest metastasis
(Klein, 2003; Pantel and Brakenhoff, 2004; Weinberg, 2007). If
this is correct, then the observation that individual esophageal
cancer cells (taken from one of the two sites of DTC isolation;
Figure 2E) share many chromosomal changes already at the
stage M0 may further indicate the progressed state of minimal
residual disease in esophageal cancer patients. However, the
few cases of which we had isolated DTCs both from lymph no-
des and bone marrow displayed heterogeneous karyotypes.
This and the overall genetic divergence of cancer cells spread
by the way of blood and lymph will may make it necessary to
screen a large number of DTCs from both ectopic sites to identify
therapy target genes. Such direct analyses of DTCs might un-
cover additional therapy target genes that have so far escaped
identification in studies of primary tumors.
Taken together, our study exemplifies that genetic markers
and therapy targets for systemic adjuvant therapies can be di-
rectly defined on disseminated cancer cells that also provide in-
formation unavailable from the primary tumor. The observed ge-
netic divergence of local and early systemic disease emphasizes
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mal systemic cancer. While we do not question that primary tu-
mors are useful to estimate prognosis, we believe that the direct
analysis of metastatic precursor cells merits further exploration.
With technologies at hand for comprehensive single-cell analysis
(Hartmann and Klein, 2006) and automated high-throughput sin-
gle-cell screening (Cristofanilli et al., 2004; Nagrath et al., 2007),
we may ultimately gather therapeutically important information
needed for the prevention of lethal metastasis.
EXPERIMENTAL PROCEDURES
Patients
The ethics committee of the University Hospital Hamburg-Eppendorf ap-
proved the study, and informed consent was obtained from all patients before
inclusion in the study. Diagnostic procedures, inclusion criteria, and character-
istics of the patients are provided in the Supplemental Data and in Table 1.
Tissue Processing
Intraoperatively, a representative sample of the primary tumor was snap frozen
in liquid nitrogen immediately after removal and stored at 80C. Five serial
cryostat sections 6–8 mm thick were cut from the tissue block. Before further
processing, the first slide was stained with hematoxylin and eosin to confirm
the tumor within the tissue.
The procedure for bone marrow aspiration, preparation, lymph node disag-
gregation, and detection of single disseminated tumor cells was performed as
previously described (Hosch et al., 2000, 2001; Klein et al., 2002a). Briefly,
2–10 ml of bone marrow was aspirated into a heparanized syringe from the up-
per iliac crest under general anesthesia before the surgical procedure. The
bone marrows were washed with Hank’s solution and were then subjected
to Ficoll-Hypaque density-gradient centrifugation (density, 1.077 g per mole)
at 900 3 g for 30 min to separate mononuclear cells. Intraoperatively, during
systematic lymphadenectomy, lymph nodes that were judged as tumor free
by the surgeon were divided into two parts. One part was sent to routine
pathology; the other part was washed twice in PBS and then minced into
1 mm pieces and diasaggregated mechanically into a single-cell suspension
by rotating knives (DAKO Medimachine, Dako, Hamburg, Germany). The cell
suspensions generated from bone marrow and lymph nodes, respectively,
were placed in a volume of 1 ml PBS on positively charged glass slides (Men-
zel, Germany) at a density of 250,000 cells per 227 mm2. After sedimentation
for 45 min, the slides were dried overnight and stored at 4C until further anal-
ysis. Immunocytological staining of 106 cells was carried out with the alkaline
phosphatase-anti-alkaline phosphatase method (APAAP) using the monoclo-
nal antibody A45-B/B3 (Micromet, Munich, Germany) against cytokeratin 8,
18, and 19 for bone marrow samples (Braun et al., 2000), and the EpCAM an-
tibody BerEP4 (Dako) was used for the lymph node samples (Izbicki et al.,
1997). Alkaline phosphatase was developed using BCIP/NBT (BioRad) as sub-
strate, and slides were covered with PBS under a cover glass for evaluation
with bright-field microscopy. In addition, 106 cells served as a control for stain-
ing with an irrelevant immunoglobulin (MOPC21, Sigma). Positive cells were
isolated from the slide in PBS containing 0.5% Igepal (Sigma) using a microma-
nipulator after removal of the cover glass. Prior to transfer to the PCR reaction
tube, all isolated single cells were placed on a fresh slide to ensure that no con-
taminating cell was coisolated.
FISH
For the evaluation of the HER2 gene amplification level, the commercially avail-
able dual-color FISH kit PathVision (Vysis Inc., Downers Grove, IL) was used.
Cryostat sections, 5 mm thick, were cut onto silanized glass slides and were
digested with 250 mg Pepsin in 50 ml 0.01 N HCl at 37C for 10–12 min.
Then the sections were fixed with 10% paraformaldehyde/50 mM MgCl2/13
PBS at room temperature. Hybridization, washing, and evaluation of the sig-
nals were performed as previously described (Stoecklein et al., 2004). Data
of 21 patients of the prospective study group were obtained from a previously
published study to extend the number of primary tumor samples (Reichelt
et al., 2007).SCOMP
Tumor cell isolation and SCOMP were exactly performed as described by
Schmidt-Kittler et al. (2003), and SCOMP of primary tumor tissue was per-
formed as described by Stoecklein et al. (2002). The CGH aberrations were de-
scribed according to the International System for Human Cytogenetic Nomen-
clature (ISCN 1995) guidelines. The web-based Progenetix software was used
to generate histograms and to perform the hierarchical cluster analysis (860
bands) from the CGH-based reverse in situ hybridization-annotated karyotype
information (Baudis and Cleary, 2001).
Quantitative PCR
Real-time PCR was performed using a LightCycler (Roche, Mannheim, Ger-
many) and Fast Start Master SYBR Green Kits (Roche) using 1 ml of primary
PCR products from the whole-genome amplification diluted 1:20 in H2O. Anal-
ysis was done using the RelQuant software (Roche) with PCR efficiency nor-
malization, and a reference sample was included for every run. Three primers
within the HER2 locus were selected, and three primers on two chromosomes
(chromosome 3 and chromosome 7) served as loading control. Primer se-
quences can be obtained upon request. Measurements showing unspecific
products in the melting curve analysis or CGH aberrations on the control loci
were discarded from further statistics. All relative expression ratios HER2/ref-
erence from duplicate measurements were compared to those from 55 normal
diploid cells. Samples showing significant difference (p < 0.05) from the control
cells in a Mann-Whitney test were classified as either ‘‘amplified’’ or ‘‘deleted’’
for HER2 depending on their mean rank value.
Double Staining
Slides were treated for 40 min with 0.1% Triton X-100 (Promega, Mannheim,
Germany) in 23 HEPES buffer (140 mM NaCl, 1.5 mM Na2HPO4, 50 mM
HEPES [Sigma Aldrich, Steinheim, Germany], pH 7.4) and 10% human anti-
body (AB) serum, then incubated with the A0485 antibody directed against
p185/HER2 (5 mg/ml, DAKO) for 30 min, washed 3 3 5 min in 23 HEPES
and subsequently incubated with a goat anti-rabbit-Cy3 antibody (7.5 mg/ml,
Jackson ImmunoResearch Laboratories, West Grove, PA). This was followed
by washing with 23 HEPES for 5 min and PBS 0.2% Tween 20 (Sigma) for
1 min and a second blocking step with 23 HEPES/10% AB serum/rabbit im-
munoglobulin X0903 (200 mg/ml, DAKO) for 40 min. Then biotinylated mab
3B10 (2 mg/ml) directed against EpCAM (Micromet, Munich, Germany) was
added for 30 min, followed by washing with PBS for 5 min and TBS for 2 3
5 min. Subsequently, we applied an AB-complex solution (DAKO) according
to the manufacturer’s instructions and washed the slides in TBS for 33 1 min.
The alkaline phosphatase activity was visualized by the ELF-97 system (Mo-
lecular Probes, Eugene, OR) according to the manufacturer’s instructions (in-
cubation time: 8 min). As negative control for the A0485 antibody we used rab-
bit IgG X0903 (5 mg/ml, DAKO), and as negative control for the EpCAM
antibody we used biotinylated MOPC 21 (2 mg/ml, Sigma). We used as positive
control PT1590 cells diluted 1:10 in human bone marrow.
Antigen-Dependent Cellular Cytotoxicity
Antigen-dependent cellular cytotoxicity (ADCC) assays were performed using
breast cancer cell line MCF7 and the esophageal cancer cell lines PT1590 and
LN1590 as target cells. LN1590 was generated from micrometastatic cells in
a lymph node (Scheunemann et al., 1999). Peripheral blood mononuclear cells
(PBMC) were prepared by Ficoll sucrose gradient density centrifugation from
fresh blood from healthy volunteer donors. Erythrocytes were removed from
collected PBMC (lysis buffer: 155 mM NH4Cl, 10 mM KHCO3, and 100 mM eth-
ylenediamine tetraacetic acid [EDTA]), and lysed erythrocytes and thrombo-
cytes were removed after centrifugation of PBMC (250 g, 15 min). Target cells
(5 3 106) were labeled with 50 mg calcein AM (Molecular Probes, Eugene, Or-
egon; C-3100MP) for 30 min at 37C in 5 ml cell culture medium (RPMI/10%
FCS). Washed PBMC were adjusted in culture medium to a density of 0.5 3
106 cells/ml, and 50,000 cells were used per replicate. Trastuzumab was di-
luted in culture medium to the required concentrations and added 10 min prior
to PBMC at room temperature to have sufficient time for antigen binding.
Washed PBMC were adjusted to 1.23 107 cells/ml in culture medium. A stan-
dard coincubation took 4 hr at 37C/5% CO2 with an effector-to-target ratio of
1:20 in a total volume of 200 ml. Subsequently, cells were collected by centri-
fugation and resuspended in FACS buffer containing 1 ml/ml PI (0.25 mg/ml).Cancer Cell 13, 441–453, May 2008 ª2008 Elsevier Inc. 451
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diated cytotoxicity was quantified in flow cytometry and based on the number
of living compared to PI-positive dead target cells in the control sample without
antibody. Sigmoidal dose-response curves typically had r2 values > 0.95 as
determined by the Graphpad PRIZM4 software.
Cell Proliferation Assay
Cultured cells were seeded into 96-well plates at a density of 1000 cells/well
24 hr prior to inhibitor (Lapatinib, Erlotinib; Vichem Chemie, Hungary) treat-
ment. The next day cells were treated with indicated concentrations of inhibitor
and cultured for 72 hr in the presence of inhibitor and FBS. Cellular metabolism
was assessed using the 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazo-
lium bromide (MTT) assay. Briefly, 20 ml of MTT solution (5 mg/ml in PBS) was
added to the cells. After 4 hr at 37C the formazan crystals formed were solu-
bilized by addition of 50 ml stop solution (10% SDS, 5% butanol, and 0.01 M
HCl). Absorbance for each well was read at 570 nm using a microplate reader.
Growth inhibition was calculated as a percentage of the untreated control. Ex-
periments were done thrice or more often in triplicates for each cell line, and
the inhibitory concentrations (IC50) were determined using the four parameter
logistic model (Sigmaplot, Systat) for curve fitting.
Flow Cytometry
Cells were seeded at a density of 2 3 104 cells/well into 12-well plates. The
next day medium was changed and cells were treated with different concen-
trations of inhibitor. After 72 hr of cultivation in the presence of inhibitor and
FBS, cells were trypsinized, collected by centrifugation, and incubated with
0.01% Triton, 0.1% sodium citrate, and 0.02 mM propidium iodide (Sigma)
in the dark at 4C. After 2 hr the cells were analyzed by flow cytometry (FACS-
Calibur, BD Bioscience) using the CellQuest Pro software. The sub-G1 popu-
lation was counted as the apoptotic population and represented as fraction of
the total cells counted.
Western Blotting
Cells were cultivated in 6 cm plates and lysed in 100 ml lysis buffer containing
1% Triton X-100, and equal amounts of protein were resolved by SDS-PAGE.
Proteins were transferred to nitrocellulose membranes (Schleicher & Schuell,
Germany), blocked for several hours in NET-gelatin and incubated at 4C over-
night with the corresponding primary antibody in NET-gelatin. The anti-HER2
(Catalog 06-562, Lot 27771) was purchased from Upstate and used in a 1:1000
dilution. Membranes were washed three times with NET-gelatin and incubated
with horseradish peroxidase-conjugated anti-rabbit secondary antibody di-
luted in Net-gelatin for 1 hr at room temperature. After additional washing
(three times), detection was done using enhanced chemiluminescence (ECL;
Western Lightning, Perkin Elmer) on X-ray films. Densitometric quantification
was done using AIDA Image Analyzer software.
RNA Interference
Cells were seeded 24 hr prior to siRNA transfection in 6 cm plates at a density
of 23 105 cells/plate. Transfection of 21-nucleotide siRNA duplexes (Ambion)
was carried out using OligofectAMINE (Invitrogen) and OPTI-MEM media
(GIBCO) without FBS.
HER2 siRNA sequence: sense, GGGAAACCUGGAACUCACCtt; antisense,
GGUGAGUUCCAGGUUUCCCtg. Control siRNA (GL2; Dharmacon) se-
quence: sense, CGUACGCGGAAUACUUCGAtt; antisense, UCGAAGUAUU
CCGCGUACGtt. After 4 hr media were changed to normal media containing
FBS, and after an additional 24 hr cells were used for further experiments.
Statistical Evaluation
For statistical analysis, contingency tables were tested with Fisher’s exact test
and whenever appropriate with the c2 test. We used log rank tests for the uni-
variate survival analysis. The primary end point was survival, as measured from
a date three months after primary surgery to the time of the last follow-up or
death. Data of patients who were still alive at the end of the study were
censored. The joint effects with already recognized prognostically relevant
variables were examined via Cox proportional hazards analysis. Histology,
pT-category, pN-category, and the presence of disseminated tumor cells
were entered stepwise forward into the model to test these covariables for452 Cancer Cell 13, 441–453, May 2008 ª2008 Elsevier Inc.possible prognostic joint effects with HER2 amplification in disseminated
tumor cells. The threshold for statistical significance was chosen at p = 0.05.
SUPPLEMENTAL DATA
The Supplemental Data include Supplemental Experimental Procedures,
one supplemental figure, and one supplemental table and can be found with
this article online at http://www.cancercell.org/cgi/content/full/13/5/441/
DC1/.
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